Softgel Source, LLC announced a new program for rapid turnaround of low-volume, custom ingestible softgels, offering production priority and no minimum order quantity to facilitate product testing. The initiative aims to support U.S. companies in bringing manufacturing back home and strengthening their competitive position in the marketplace. Kevin McDowell, Founder and CEO of Softgel Source, stated that U.S. companies face both challenges and opportunities in domestic manufacturing. The company's Portland location positions it to help biotech and pharmaceutical businesses rapidly develop and test new softgel products.
This expansion reflects broader trends in U.S. manufacturing, with Deloitte and The Manufacturing Institute projecting continued job growth and biotech manufacturing expected to grow 6–8% annually through 2030. Businesses dependent on offshore manufacturing increasingly face disrupted supply chains, long lead times, and shifting tariffs. McDowell emphasized that manufacturers investing in domestic product development will be best positioned to thrive. Softgel Source helps companies address these issues by offering U.S.-manufactured softgels with fast turnaround rates, serving as both a primary development partner and backup production source when offshore suppliers falter.
The program also addresses regulatory challenges, as constant changes in U.S. and international regulations require companies to reformulate and retest products on short notice. McDowell noted that a local U.S. manufacturer with fast turnaround and low minimum order quantities is ideal for time-sensitive reformulation and testing requirements. More information about the company's services is available at https://softgelsource.com.
Softgel Source focuses on custom softgel manufacturing for vitamin, medication, supplement, and pet product industries, specializing in responsive, rapid turnaround of prototype production and low-to-moderate volume manufacturing for U.S.-based clients. The company's approach supports the growing movement toward domestic manufacturing resilience and regulatory compliance in the ingestible products sector. This development matters because it represents a strategic response to ongoing supply chain vulnerabilities that have affected numerous industries in recent years, offering companies a practical solution to maintain product development momentum while reducing dependency on unpredictable international suppliers.
The implications of this announcement extend beyond immediate business operations to broader economic and strategic considerations. By enabling faster product testing and development cycles with no minimum order requirements, Softgel Source lowers barriers to innovation for smaller companies and startups that might otherwise struggle with offshore manufacturing constraints. This supports the reshoring movement that has gained momentum as companies seek to build more resilient supply chains closer to their primary markets. The program's timing aligns with projected growth in biotech manufacturing and increasing regulatory complexity, positioning domestic manufacturers to capture value from these trends while helping clients navigate an evolving compliance landscape.
